Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus DOXY LEMMON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus DOXY LEMMON.
ACHROMYCIN vs DOXY-LEMMON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg orally or intravenously once daily.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life: 18-22 hours (mean ~20 hours) in adults with normal renal function. Clinically, this supports twice-daily dosing; prolonged in severe renal impairment (up to 40-60 hours) or hepatic impairment.
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal (approx. 40% as unchanged drug via glomerular filtration), biliary/fecal (approx. 60% as active and inactive metabolites, with significant enterohepatic recycling). Dose adjustment not required in mild renal impairment, but caution in severe hepatic dysfunction.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic